Cosmo Pharmaceuticals N.V. provided earnings guidance for the year 2022. For the year, the company expects Total revenues in the range of 90 million to 100 million against 65.1 million in 2021. Operating profit in the range of 20 million to 25 million against 7 million to 10 million in 2021.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
71.4 CHF | +0.28% | +3.18% | +40.28% |
Mar. 20 | Transcript : Cosmo Pharmaceuticals N.V. - Analyst/Investor Day | |
Mar. 20 | Cosmo Pharmaceuticals N.V. Proposes Dividend Payment for 2024 | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+40.28% | 1.26B | |
+24.60% | 654B | |
+24.08% | 552B | |
-5.63% | 356B | |
+15.37% | 319B | |
+7.38% | 295B | |
+3.26% | 211B | |
+0.78% | 206B | |
-9.69% | 147B | |
-6.63% | 144B |
- Stock Market
- Equities
- COPN Stock
- News Cosmo Pharmaceuticals N.V.
- Cosmo Pharmaceuticals N.V. Provides Earnings Guidance for the Year 2022